Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV000797712 | SCV000937287 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2018-10-03 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with ALK-related disease. This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with alanine at codon 687 of the ALK protein (p.Thr687Ala). The threonine residue is highly conserved and there is a small physicochemical difference between threonine and alanine. |
| Ambry Genetics | RCV002422720 | SCV002727607 | uncertain significance | Hereditary cancer-predisposing syndrome | 2017-01-27 | criteria provided, single submitter | clinical testing | The p.T687A variant (also known as c.2059A>G), located in coding exon 12 of the ALK gene, results from an A to G substitution at nucleotide position 2059. The threonine at codon 687 is replaced by alanine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |